Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients

NCT02698735 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT02698735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02698735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients
Lead sponsor
University of Southern California
Phase
Phase 1/2
Overall status
Completed
Start date
February 25, 2016
Completion date
June 30, 2017
Enrollment
5 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recessive dystrophic epidermolysis bullosa